Stroke:肾功能与卒中后30天和1年死亡率和再入院率的关系

2018-11-10 xing.T MedSci原创

由此可见,在缺血性卒中住院后的第一年内,入院时eGFR和透析状态与卒中后死亡率和再入院率有关。肾功能应纳入卒中后结局的风险分层模型中。

肾功能障碍在因缺血性卒中住院的患者中很常见。了解肾脏疾病与卒中后结局的关系适当调整病例组合对于结局研究、支付模型和风险标准化的医院再入院率非常重要。

近日,卒中领域权威杂志Stroke上发表了一篇研究文章,在这项针对缺血性卒中入院的医疗保险费用患者的队列研究中,调查多变量Cox比例风险模型被用于确定估计肾小球滤过率( eGFR)和透析状态与出院后30天和1年死亡率和再次入院之间的独立关联。

在204652名出院患者[中位年龄[25-75百分位]为80岁[73.0-86.0],女性占57.6%,白人占79.8%)中,48.8%的参与者eGFR≥60,26.5%的参与者eGFR为45~59,16.3%的参与者eGFR为30~44,5.1%的参与者eGFR为15~29,0.6%的参与者eGFR<15,未进行透析,2.8%的参与者接受透析。与eGFR≥60相比,调整相关变量后,eGFR<45与30天死亡率增加相关,eGFR<15且未透析的风险最高(风险比[HR]为2.09; 95%CI为1.66-2.63)。eGFR<60与1年卒中后死亡率增加相关,在透析患者中最高​(HR为2.65; 95%CI为2.49-2.81)。透析也与最高30天和1年再住院率(HR为2.10; 95%CI为1.95-2.26和HR为2.55; 95%CI为2.44-2.66)和30天以及1天年复合死亡率和再住院率(HR为2.04; 95%CI为1.90-2.18和HR为2.46; 95%CI为2.36-2.56)相关。

由此可见,在缺血性卒中住院后的第一年内,入院时eGFR和透析状态与卒中后死亡率和再入院率有关。肾功能应纳入卒中后结局的风险分层模型中。

原始出处:

Nada El Husseini,et al.Association of Kidney Function With 30-Day and 1-Year Poststroke Mortality and Hospital Readmission Get With the Guidelines-Stroke.Stroke. 2018.https://www.ahajournals.org/doi/10.1161/STROKEAHA.118.022011

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671355, encodeId=f03816e13554d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 04 17:21:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977805, encodeId=6f5b19e780540, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Mar 06 18:21:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850694, encodeId=cc111850694ae, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Jul 21 18:21:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529981, encodeId=8a42152998157, content=<a href='/topic/show?id=bcc5306146d' target=_blank style='color:#2F92EE;'>#再入院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30614, encryptionId=bcc5306146d, topicName=再入院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a1e11986162, createdName=yzh403, createdTime=Mon Nov 12 01:21:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352265, encodeId=6565352265e8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 11 11:29:38 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026209, encodeId=fa7b1026209b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Nov 10 13:21:00 CST 2018, time=2018-11-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671355, encodeId=f03816e13554d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 04 17:21:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977805, encodeId=6f5b19e780540, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Mar 06 18:21:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850694, encodeId=cc111850694ae, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Jul 21 18:21:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529981, encodeId=8a42152998157, content=<a href='/topic/show?id=bcc5306146d' target=_blank style='color:#2F92EE;'>#再入院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30614, encryptionId=bcc5306146d, topicName=再入院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a1e11986162, createdName=yzh403, createdTime=Mon Nov 12 01:21:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352265, encodeId=6565352265e8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 11 11:29:38 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026209, encodeId=fa7b1026209b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Nov 10 13:21:00 CST 2018, time=2018-11-10, status=1, ipAttribution=)]
    2019-03-06 smlt2008
  3. [GetPortalCommentsPageByObjectIdResponse(id=1671355, encodeId=f03816e13554d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 04 17:21:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977805, encodeId=6f5b19e780540, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Mar 06 18:21:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850694, encodeId=cc111850694ae, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Jul 21 18:21:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529981, encodeId=8a42152998157, content=<a href='/topic/show?id=bcc5306146d' target=_blank style='color:#2F92EE;'>#再入院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30614, encryptionId=bcc5306146d, topicName=再入院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a1e11986162, createdName=yzh403, createdTime=Mon Nov 12 01:21:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352265, encodeId=6565352265e8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 11 11:29:38 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026209, encodeId=fa7b1026209b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Nov 10 13:21:00 CST 2018, time=2018-11-10, status=1, ipAttribution=)]
    2019-07-21 yese
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671355, encodeId=f03816e13554d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 04 17:21:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977805, encodeId=6f5b19e780540, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Mar 06 18:21:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850694, encodeId=cc111850694ae, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Jul 21 18:21:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529981, encodeId=8a42152998157, content=<a href='/topic/show?id=bcc5306146d' target=_blank style='color:#2F92EE;'>#再入院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30614, encryptionId=bcc5306146d, topicName=再入院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a1e11986162, createdName=yzh403, createdTime=Mon Nov 12 01:21:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352265, encodeId=6565352265e8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 11 11:29:38 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026209, encodeId=fa7b1026209b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Nov 10 13:21:00 CST 2018, time=2018-11-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1671355, encodeId=f03816e13554d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 04 17:21:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977805, encodeId=6f5b19e780540, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Mar 06 18:21:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850694, encodeId=cc111850694ae, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Jul 21 18:21:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529981, encodeId=8a42152998157, content=<a href='/topic/show?id=bcc5306146d' target=_blank style='color:#2F92EE;'>#再入院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30614, encryptionId=bcc5306146d, topicName=再入院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a1e11986162, createdName=yzh403, createdTime=Mon Nov 12 01:21:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352265, encodeId=6565352265e8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 11 11:29:38 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026209, encodeId=fa7b1026209b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Nov 10 13:21:00 CST 2018, time=2018-11-10, status=1, ipAttribution=)]
    2018-11-11 医者仁心5538

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1671355, encodeId=f03816e13554d, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 04 17:21:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977805, encodeId=6f5b19e780540, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Mar 06 18:21:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850694, encodeId=cc111850694ae, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Jul 21 18:21:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529981, encodeId=8a42152998157, content=<a href='/topic/show?id=bcc5306146d' target=_blank style='color:#2F92EE;'>#再入院率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30614, encryptionId=bcc5306146d, topicName=再入院率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a1e11986162, createdName=yzh403, createdTime=Mon Nov 12 01:21:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352265, encodeId=6565352265e8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 11 11:29:38 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026209, encodeId=fa7b1026209b8, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Sat Nov 10 13:21:00 CST 2018, time=2018-11-10, status=1, ipAttribution=)]
    2018-11-10 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

相关资讯

J Am Soc Nephrol:年龄和肾功能不同的晚期CKD老年患者,透析vs药物对生存期的影响

2018年8月,发表在《J Am Soc Nephrol》的一项由美国学者进行的分析,在不同年龄和肾功能的晚期CKD老年患者中,考察了透析vs药物管理与生存期之间的相关性

JAHA:白蛋白尿、肾功能降低与ST段和非ST段抬高心肌梗死风险的关系

由此可见,无论肾功能如何,尿中白蛋白升高与NSTEMI和STEMI的高风险相关,而单独降低的肾功能与更高的NSTEMI风险相关。

Hypertension:早产年轻人肾脏大小、肾功能、血管紧张素和血压分析

由此可见,与足月产成人相比,早产的青年人肾脏较小,尿白蛋白与肌酐比值较高,血压和循环Ang I水平也较高。肾脏较小的早产成人具有较高的血压。

JASN:可溶性TNFR-1浓度与肾功能长期下降的关系

由此可见,血清sTNFR-1浓度升高与十年内eGFR下降速度加快有关,并且与先前已知的肾病进展危险因素无关。

Circulation:采用沙普替利/缬沙坦治疗慢性肾病,额外具有降血压和心肌标志物的作用

沙普替利/缬沙坦可降低射血分数降低的心力衰竭患者的心血管死亡风险,但其对中重度慢性肾病患者肾功能和心脏生物标志物的影响尚不明确。UK HARP-III期试验是一个随机化的双盲试验,招募了414位肾小球滤过率(GFR)在20-60mL/min/1.73m2的患者,受试患者被随机分至沙普替利/缬沙坦组(97/103mg 2/日)或厄贝沙坦组(300mg 1/日),各207位患者。主要结点:12个月时,

JASN:2型糖尿病患者服用依帕列净与肾功能下降的关系

由此可见,依帕列净的血流动力学效应与肾小球内压的降低有关,可能有助于肾功能的长期保存。